anadelumab for treatment of COVID-19 disease - COVID-LA

Radboud University Medical Center0 个研究点目标入组 80 人开始时间: 2020年5月14日最近更新: 2021年5月17日

适应症

试验速览

暂无简介。

•1. Patient is SARS-COV2 positive (PCR)
•2. Without oxygen a saturation below 90% and/or at least 3L/min oxygen dependent
•3. Patient is 16 years and older
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 3
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 37

•1. Has previously participated in this study
•2. Acute myocardial or cerebral ischemic event at time of enrolment
•3. Receiving an agent that is specified as an intervention in this domain as a usual medication prior to this hospitalization will exclude a patient from receiving that agent
•4. A baseline alanine aminotransferase or an aspartate aminotransferase that is more than five times the upper limit of normal will result in exclusion from receiving lanadelumab
•5. Patient is known hypersensitive to full human monoclonal antibodies.
•6. Patient is pregnant or breast feeding

发起方